Trial Profile
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3375880 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Torudokimab (Primary) ; Torudokimab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 1 Nov 2018 to 19 Nov 2018.
- 23 Aug 2018 Planned primary completion date changed from 1 Nov 2018 to 19 Nov 2018.